- Home
- SLQT vs EYPT Comparison
SLQT vs EYPT Comparison
Compare SLQT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLQT | EYPT |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 1.1B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SLQT | EYPT |
|---|---|---|
| Price | $0.61 | $13.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.88 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-11-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,526,594,000.00 | $7,539,000.00 |
| Revenue This Year | $11.42 | N/A |
| Revenue Next Year | $7.76 | $1,031.72 |
| P/E Ratio | $63.00 | ★ N/A |
| Revenue Growth | ★ 15.50 | N/A |
| 52 Week Low | $0.60 | $3.91 |
| 52 Week High | $3.73 | $19.11 |
Technical Indicators
Market Signals| Indicator | SLQT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 29.52 | 39.40 |
| Support Level | N/A | $12.47 |
| Resistance Level | $0.94 | $13.32 |
| Average True Range (ATR) | 0.05 | 0.80 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 7.94 | 23.52 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.